B. McLaughlin Associates, Inc (BMA)

bmaresearch.com

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

CLEARMIND MEDICINE TO PARTNER WITH MICRODOSE FOR PSYCHEDELIC CAPITAL

Clearmind Medicine Inc. | March 25, 2022

news image

Clearmind Medicine Inc. a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event. While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders. ...

Read More

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

news image

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More

Pharma Tech

BIOMIND LABS ANNOUNCES DESIGN OF A PHARMACEUTICAL FORM FOR PSYCHEDELIC DRUG DELIVERY USING 3D PRINTING

Biomind Labs | November 25, 2021

news image

Biomind Labs Inc. a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various in...

Read More

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

news image

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More
news image

Business Insights

CLEARMIND MEDICINE TO PARTNER WITH MICRODOSE FOR PSYCHEDELIC CAPITAL

Clearmind Medicine Inc. | March 25, 2022

Clearmind Medicine Inc. a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event. While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders. ...

Read More
news image

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More
news image

Pharma Tech

BIOMIND LABS ANNOUNCES DESIGN OF A PHARMACEUTICAL FORM FOR PSYCHEDELIC DRUG DELIVERY USING 3D PRINTING

Biomind Labs | November 25, 2021

Biomind Labs Inc. a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various in...

Read More
news image

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us